Pneumococcal 21-Valent Conjugate Vaccine Dosage

Medically reviewed by Drugs.com. Last updated on Jul 23, 2024.

Usual Adult Dose for Infection Prophylaxis

0.5 mg IM ONCE

Comments:

The US FDA issued a Biologics License Application (BLA) to allow for the accelerated approval of this vaccine based on immune response in clinical trials. Continued US FDA approval may depend upon continued clinical benefit in confirmatory trials.
For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Uses:

Active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B
Active immunization for the prevention of pneumonia caused by S pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B

0.5 mg IM ONCE

Comments:

The US FDA issued a Biologics License Application (BLA) to allow for the accelerated approval of this vaccine based on immune response in clinical trials. Continued US FDA approval may depend upon continued clinical benefit in confirmatory trials.
For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Uses:

Active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B
Active immunization for the prevention of pneumonia caused by S pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B

0.5 mg IM ONCE

Comments:

The US FDA issued a Biologics License Application (BLA) to allow for the accelerated approval of this vaccine based on immune response in clinical trials. Continued US FDA approval may depend upon continued clinical benefit in confirmatory trials.
For additional information: https://www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and-policy-framework/emergency-use-authorization

Uses:

Active immunization for the prevention of disease caused by Streptococcus pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B
Active immunization for the prevention of pneumonia caused by S pneumoniae serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15C, 16F, 17F, 19A, 20A, 22F, 23A, 23B, 24F, 31, 33F, and 35B

Data not available

Data not available

CONTRAINDICATIONS:

Patients with a known history of severe allergic reaction to the active component or any of the ingredients
Patients with a known history of severe allergic reaction to the diphtheria toxoid

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Data not available

Administration advice:

Storage requirements:

Reconstitution/preparation techniques:

General:

Each dose must contain 0.5 mL of vaccine, and each dose contains 84 mcg of pneumococcal polysaccharide antigen.
This vaccine does not contain preservatives.

Patient advice:

To report suspected adverse reactions, contact the Vaccine Adverse Event Reporting System (VAERS): https://vaers.hhs.gov
Read the US FDA-approved patient labeling.